Onconetix (ONCO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Mar, 2026Executive summary
Special meeting scheduled for April 30, 2026, to vote on two key proposals: a reverse stock split amendment and potential adjournment to solicit more proxies if needed.
The Board unanimously recommends voting in favor of both proposals, citing the need to maintain Nasdaq listing compliance.
Record date for voting eligibility is March 13, 2026, with 3,473,352 shares of common stock outstanding.
Proxy solicitation is managed by Alliance Advisors, with an estimated fee of $21,000 plus expenses.
Voting matters and shareholder proposals
Proposal 1: Grant Board authority to amend the Charter for one or more reverse stock splits at ratios between 1-for-2 and 1-for-10, not exceeding 1-for-100 in aggregate, within one year of the meeting.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit proxies for Proposal 1.
Both proposals require a majority of votes cast by stockholders present or represented by proxy.
All proposals are considered routine, allowing brokers discretionary voting authority.
Board of directors and corporate governance
The Board retains discretion to implement or abandon any reverse stock split within the approved range and timeframe.
No changes to the rights or preferences of existing stockholders, except for treatment of fractional shares.
Latest events from Onconetix
- Net loss narrowed in 2025, but liquidity and going concern risks persist amid ongoing reliance on Proclarix.ONCO
Q4 202513 Mar 2026 - Proxy seeks approval for key governance, capital, and strategic proposals amid financial challenges.ONCO
Proxy Filing13 Feb 2026 - Proxy seeks approval for director elections, equity plan, stock split, major share issuances, and auditor.ONCO
Proxy Filing13 Feb 2026 - Proxy seeks approval for key proposals amid financial challenges and strategic shifts.ONCO
Proxy Filing13 Feb 2026 - Proxy seeks approval for director elections, equity plan expansion, reverse split, and major share issuances.ONCO
Proxy Filing13 Feb 2026 - Acute financial distress and urgent capital needs as focus shifts to Proclarix commercialization.ONCO
Registration Filing13 Feb 2026 - Biotech firm with a key prostate cancer diagnostic faces urgent capital needs and strategic uncertainty.ONCO
Registration Filing13 Feb 2026 - Shareholders to vote on director elections, PIPE financings, and auditor ratification.ONCO
Proxy Filing13 Feb 2026 - Equity line of credit enables up to $25M in funding but poses major dilution and liquidity risks.ONCO
Registration Filing13 Feb 2026